CA2339023C - An in-vitro method of detecting and diagnosing acute coronary syndromes - Google Patents
An in-vitro method of detecting and diagnosing acute coronary syndromes Download PDFInfo
- Publication number
- CA2339023C CA2339023C CA002339023A CA2339023A CA2339023C CA 2339023 C CA2339023 C CA 2339023C CA 002339023 A CA002339023 A CA 002339023A CA 2339023 A CA2339023 A CA 2339023A CA 2339023 C CA2339023 C CA 2339023C
- Authority
- CA
- Canada
- Prior art keywords
- choline
- cctd
- group
- enyl
- alk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 143
- 238000000338 in vitro Methods 0.000 title claims abstract description 17
- 208000004476 Acute Coronary Syndrome Diseases 0.000 title claims description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 58
- 229960001231 choline Drugs 0.000 claims abstract description 58
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 56
- 239000007795 chemical reaction product Substances 0.000 claims abstract description 50
- 206010000891 acute myocardial infarction Diseases 0.000 claims abstract description 34
- 239000000126 substance Substances 0.000 claims abstract description 34
- -1 plasmalogens Chemical compound 0.000 claims abstract description 29
- HTZINLFNXLXRBC-CQLBIITFSA-N 1-(1Z-hexadecenyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC\C=C/OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C HTZINLFNXLXRBC-CQLBIITFSA-N 0.000 claims abstract description 28
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical class CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims abstract description 26
- XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical class OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 claims abstract description 24
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims abstract description 24
- 229950004354 phosphorylcholine Drugs 0.000 claims abstract description 24
- 210000001124 body fluid Anatomy 0.000 claims abstract description 22
- 239000010839 body fluid Substances 0.000 claims abstract description 22
- 230000001900 immune effect Effects 0.000 claims abstract description 22
- 150000002314 glycerols Chemical class 0.000 claims abstract description 14
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 4
- 101100313185 Homo sapiens CCT4 gene Proteins 0.000 claims description 155
- 102100029958 T-complex protein 1 subunit delta Human genes 0.000 claims description 155
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 238000003745 diagnosis Methods 0.000 claims description 20
- 229940112042 peripherally acting choline derivative muscle relaxants Drugs 0.000 claims description 18
- 150000003248 quinolines Chemical class 0.000 claims description 18
- 238000011156 evaluation Methods 0.000 claims description 13
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 12
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 9
- 238000005481 NMR spectroscopy Methods 0.000 claims description 8
- 210000002700 urine Anatomy 0.000 claims description 7
- 229960003624 creatine Drugs 0.000 claims description 6
- 239000006046 creatine Substances 0.000 claims description 6
- 238000003909 pattern recognition Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 abstract description 17
- 230000007717 exclusion Effects 0.000 abstract 1
- 238000001646 magnetic resonance method Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 34
- 229940067631 phospholipid Drugs 0.000 description 19
- 206010061216 Infarction Diseases 0.000 description 16
- 230000007574 infarction Effects 0.000 description 16
- 239000012071 phase Substances 0.000 description 16
- 150000003904 phospholipids Chemical class 0.000 description 16
- 102000015439 Phospholipases Human genes 0.000 description 13
- 108010064785 Phospholipases Proteins 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 206010002383 Angina Pectoris Diseases 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000036407 pain Effects 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 238000013399 early diagnosis Methods 0.000 description 8
- 230000002107 myocardial effect Effects 0.000 description 8
- 235000008979 vitamin B4 Nutrition 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 102000011420 Phospholipase D Human genes 0.000 description 6
- 108090000553 Phospholipase D Proteins 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000011325 microbead Substances 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102100037611 Lysophospholipase Human genes 0.000 description 5
- 102000014384 Type C Phospholipases Human genes 0.000 description 5
- 108010079194 Type C Phospholipases Proteins 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000004611 spectroscopical analysis Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102000004903 Troponin Human genes 0.000 description 4
- 108090001027 Troponin Proteins 0.000 description 4
- 238000002306 biochemical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108020002496 Lysophospholipase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000002586 coronary angiography Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 150000008105 phosphatidylcholines Chemical class 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 102000036675 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 2
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 102000004987 Troponin T Human genes 0.000 description 2
- 108090001108 Troponin T Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- HJJPJSXJAXAIPN-UHFFFAOYSA-N arecoline Chemical compound COC(=O)C1=CCCN(C)C1 HJJPJSXJAXAIPN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000011152 fibreglass Substances 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007576 microinfarct Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 238000004305 normal phase HPLC Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035778 pathophysiological process Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- HRQDDZWMEGEOOO-UHFFFAOYSA-N 2-trimethylsilylpropanoic acid Chemical compound OC(=O)C(C)[Si](C)(C)C HRQDDZWMEGEOOO-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 241000973887 Takayama Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003796 diagnosis of exclusion Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000011141 high resolution liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 238000012594 liquid chromatography nuclear magnetic resonance Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 108010077055 methylated bovine serum albumin Proteins 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010995 multi-dimensional NMR spectroscopy Methods 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000000079 presaturation Methods 0.000 description 1
- 230000001536 pro-arrhythmogenic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Nuclear Medicine (AREA)
- Electrotherapy Devices (AREA)
- Excavating Of Shafts Or Tunnels (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19836617A DE19836617C2 (de) | 1998-08-12 | 1998-08-12 | In vitro Verfahren zur Erkennung und Diagnostik akuter koronarer Syndrome |
| DE19836617.5 | 1998-08-12 | ||
| PCT/EP1999/005911 WO2000010014A1 (de) | 1998-08-12 | 1999-08-11 | In vitro verfahren zur erkennung und diagnostik akuter koronarer syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2339023A1 CA2339023A1 (en) | 2000-02-24 |
| CA2339023C true CA2339023C (en) | 2009-11-17 |
Family
ID=7877351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002339023A Expired - Fee Related CA2339023C (en) | 1998-08-12 | 1999-08-11 | An in-vitro method of detecting and diagnosing acute coronary syndromes |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6830932B1 (https=) |
| EP (1) | EP1104547B1 (https=) |
| JP (1) | JP2002522791A (https=) |
| AT (1) | ATE242488T1 (https=) |
| AU (1) | AU761226B2 (https=) |
| CA (1) | CA2339023C (https=) |
| CZ (1) | CZ299988B6 (https=) |
| DE (2) | DE19836617C2 (https=) |
| DK (1) | DK1104547T3 (https=) |
| ES (1) | ES2201764T3 (https=) |
| HU (1) | HUP0102984A3 (https=) |
| IL (2) | IL141152A0 (https=) |
| NZ (1) | NZ509406A (https=) |
| PT (1) | PT1104547E (https=) |
| WO (1) | WO2000010014A1 (https=) |
| ZA (1) | ZA200101972B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE397938T1 (de) * | 2000-05-19 | 2008-07-15 | Amylin Pharmaceuticals Inc | Behandlung des akuten koronaren syndroms mit glp- 1 |
| US7262017B2 (en) * | 2001-09-14 | 2007-08-28 | Torrey Pines Institute For Molecular Studies | Diagnostic markers for ischemia |
| US7491504B2 (en) * | 2005-11-22 | 2009-02-17 | Frantz Biomarkers, Llc | Method for detecting ovarian cancer |
| US20080020472A1 (en) * | 2005-11-22 | 2008-01-24 | Frantz Biomarkers, Llc | Method for detecting an inflammatory disease or cancer |
| WO2007092331A2 (en) * | 2006-02-02 | 2007-08-16 | Esa Biosciences, Inc. | Detection methods and devices |
| US20070281321A1 (en) * | 2006-05-31 | 2007-12-06 | Esa Biosciences, Inc. | Biosensor for measurement of species in a body fluid |
| JP5220842B2 (ja) * | 2007-04-13 | 2013-06-26 | フェノメノーム ディスカバリーズ インク | プラスマロゲン欠乏症が媒介する加齢に伴う疾患の診断及びリスク評価のための方法 |
| US7811749B2 (en) * | 2008-04-21 | 2010-10-12 | Abbott Laboratories | Measuring free choline to determine suitability of erythrocytes for transfusion |
| JP5662060B2 (ja) * | 2010-06-04 | 2015-01-28 | 学校法人帝京大学 | 検出方法 |
| JP2012024014A (ja) * | 2010-07-23 | 2012-02-09 | Asahi Kasei Pharma Kk | 全血コリンの測定方法 |
| CN102998274A (zh) * | 2012-11-30 | 2013-03-27 | 华南理工大学 | 一种快速测定制浆黑液中总硫含量的方法 |
| CN111505131B (zh) * | 2020-01-02 | 2023-03-31 | 东莞东华医院有限公司 | 基于血清代谢组学改变建立的预测冠心病斑块不稳定性临床模型 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1598739C3 (de) * | 1965-01-26 | 1973-10-11 | Merck Patent Gmbh, 6100 Darmstadt | Mittel zur Bestimmung der Chohnesteraseaktivitat im Serum |
| WO1991002532A2 (en) * | 1989-08-14 | 1991-03-07 | Queen's University At Kingston | Method for stimulating fibrinolytic effect |
| US5604105B1 (en) * | 1990-10-12 | 1999-08-24 | Spectral Diagnostics Inc | Method and device for diagnosingand distinguishing chest pain in early onset thereof |
-
1998
- 1998-08-12 DE DE19836617A patent/DE19836617C2/de not_active Expired - Fee Related
-
1999
- 1999-08-11 HU HU0102984A patent/HUP0102984A3/hu unknown
- 1999-08-11 PT PT99942859T patent/PT1104547E/pt unknown
- 1999-08-11 AT AT99942859T patent/ATE242488T1/de not_active IP Right Cessation
- 1999-08-11 DE DE59905860T patent/DE59905860D1/de not_active Expired - Lifetime
- 1999-08-11 US US09/762,691 patent/US6830932B1/en not_active Expired - Fee Related
- 1999-08-11 NZ NZ509406A patent/NZ509406A/en not_active IP Right Cessation
- 1999-08-11 ES ES99942859T patent/ES2201764T3/es not_active Expired - Lifetime
- 1999-08-11 IL IL14115299A patent/IL141152A0/xx active IP Right Grant
- 1999-08-11 EP EP99942859A patent/EP1104547B1/de not_active Expired - Lifetime
- 1999-08-11 JP JP2000565402A patent/JP2002522791A/ja active Pending
- 1999-08-11 AU AU56219/99A patent/AU761226B2/en not_active Ceased
- 1999-08-11 CZ CZ20010281A patent/CZ299988B6/cs not_active IP Right Cessation
- 1999-08-11 WO PCT/EP1999/005911 patent/WO2000010014A1/de not_active Ceased
- 1999-08-11 CA CA002339023A patent/CA2339023C/en not_active Expired - Fee Related
- 1999-08-11 DK DK99942859T patent/DK1104547T3/da active
-
2001
- 2001-01-29 IL IL141152A patent/IL141152A/en not_active IP Right Cessation
- 2001-03-09 ZA ZA200101972A patent/ZA200101972B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1104547B1 (de) | 2003-06-04 |
| EP1104547A1 (de) | 2001-06-06 |
| CA2339023A1 (en) | 2000-02-24 |
| DE19836617A1 (de) | 2000-03-16 |
| ATE242488T1 (de) | 2003-06-15 |
| CZ2001281A3 (cs) | 2001-07-11 |
| HUP0102984A3 (en) | 2005-06-28 |
| AU761226B2 (en) | 2003-05-29 |
| DE19836617C2 (de) | 2001-02-08 |
| HUP0102984A2 (hu) | 2001-11-28 |
| IL141152A (en) | 2006-08-01 |
| DE59905860D1 (de) | 2003-07-10 |
| CZ299988B6 (cs) | 2009-01-14 |
| IL141152A0 (en) | 2002-02-10 |
| ZA200101972B (en) | 2003-07-02 |
| ES2201764T3 (es) | 2004-03-16 |
| NZ509406A (en) | 2003-05-30 |
| WO2000010014A1 (de) | 2000-02-24 |
| DK1104547T3 (da) | 2003-09-29 |
| PT1104547E (pt) | 2003-10-31 |
| JP2002522791A (ja) | 2002-07-23 |
| AU5621999A (en) | 2000-03-06 |
| US6830932B1 (en) | 2004-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beaumont et al. | Classification of hyperlipidaemias and hyperlipoproteinaemias. | |
| CA2339023C (en) | An in-vitro method of detecting and diagnosing acute coronary syndromes | |
| Petroff et al. | High‐resolution proton magnetic resonance analysis of human cerebrospinal fluid | |
| AU2012288742A1 (en) | Means and methods for diagnosing and monitoring heart failure in a subject | |
| US20100081160A1 (en) | Method for Diagnosing Multiple Sclerosis | |
| WO2007110357A2 (en) | Means and method for diagnosing diabetes | |
| WO2001014881A1 (en) | Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-ms immune response | |
| CA2787297A1 (en) | Means and methods for diagnosing heart failure in a subject | |
| AU2011260390A1 (en) | Means and methods for diagnosing pancreatic cancer in a subject | |
| EP2419742A1 (en) | Detecting phospholipidosis and diagnosing lysosomal storage disorders | |
| CA2845117A1 (en) | Means and methods for assessing kidney toxicity | |
| US20050142613A1 (en) | Test for the rapid evaluation of ischemic states and kits | |
| US5443989A (en) | Method for assessing fetal lung maturity using amniotic fluid samples | |
| DE60311871T2 (de) | Verfahren zur detektion von prp unter verwendung ein makrozyklischen ligand | |
| AU2012264688A1 (en) | Methods for diagnosing multiple sclerosis | |
| US7449338B2 (en) | Tests for the rapid evaluation of ischemic states and kits | |
| Lin et al. | Positive interference from contrast media in cardiac troponin I immunoassays | |
| PL238142B1 (pl) | Sposób diagnozowania boreliozowego zapalenia stawów, sposób różnicowego diagnozowania boreliozowego zapalenia stawów oraz zastosowania lizofosfatydyloetanoloaminy jako biomarkera | |
| EP1412747B1 (en) | Method and antibody for detecting alcohol consumption | |
| Kuwabara et al. | Study on the erythrocytes from myotonic dystrophy with multi‐nuclear NMR | |
| Nicholson | High resolution nuclear magnetic resonance spectroscopy in clinical chemistry and disease diagnosis | |
| Chapman et al. | " F NMR Magnetization Transfer between | |
| Carbury | The establishment of a therapeutic monitoring service for digoxin | |
| Moldoveanu et al. | Postmortem Specificity of Troponin for Acute Myocardial Infarction Diagnosis Through Qualitative Dosing from Pericardial Fluid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |